Loading
ABBV-706 / Etoposide / Atezolizumab · Phase 2 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for an investigational combination therapy (ABBV-706 plus atezolizumab) in previously untreated extensive-stage SCLC, comparing two doses against standard of care. No results are reported in this registry record; the study is actively recruiting.
Phase 2, Interventional, Randomized, Sequential, Open label, Treatment purpose. Small Cell Lung Cancer; age from 18 Years. Intervention: Safety Lead-In: ABBV-706 Dose A; Safety Lead-In: ABBV-706 Dose B; Safety Lead-In: Stand of Care (SOC); Expansion: ABBV-706 Dose A; Expansion: ABBV-706 Dose B; Expansion: SOC. Compared with: Standard of care: intravenous etoposide, carboplatin, atezolizumab, and optional lurbinectedin. n = 180. 67 sites across 13 countries.
This is a Phase 2 trial registration for an investigational combination therapy (ABBV-706 plus atezolizumab) in previously untreated extensive-stage SCLC, comparing two doses against standard of care. No results are reported in this registry record; the study is actively recruiting.
This is a registry record only; no efficacy or safety results are reported.
Clinicians should recognize this as an early-phase evaluation of a novel agent in SCLC; results are not yet available and should not inform current practice. The trial is actively recruiting and may inform future treatment options pending efficacy and safety data.
This is a Phase 2 trial registration with no results reported; it describes a planned study of an investigational drug in combination therapy for extensive-stage SCLC, addressing dose optimization and safety.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as an early-phase evaluation of a novel agent in SCLC; results are not yet available and should not inform current practice. The trial is actively recruiting and may inform future treatment options pending efficacy and safety data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07155174). This is a study registration, not published results. Lead sponsor: AbbVie. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 180 participants (ESTIMATED). Conditions: Small Cell Lung Cancer. Interventions: DRUG: ABBV-706; DRUG: Atezolizumab; DRUG: Etoposide; DRUG: Carboplatin; DRUG: Carboplatin; DRUG: Lurbinectedin. Primary outcome measures: Number of Participants with Adverse Events (AE)s , Up to 69.5 Months; Progression-Free Survival (PFS) Based on Investigator Assessment , Up to Approximately 24 Months. Brief summary: Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.